Korea United Pharm said Monday that it posted sales of 288.7 billion won ($196.2 million) last year, up 3.5 percent from 2023, marking the best performance in its history.

The company attributed the results to the launch of new products and continued growth of existing improved drugs. In particular, the company analyzed that the steady increase in the share of sales of improved drugs positively impacted its overall profit improvement.

Korea United Pharm’s operating profit also recorded a record high of 56.3 billion won, up 2.4 percent. Net profit closed at 32.3 billion won due to increased one-time factors.

Improved drugs, including Cilostan CR Tab., continued to grow steadily and contributed significantly to sales. Blockbuster items increased to six, as Rabemini Tab. surpassed 10 billion won in sales.

Korea United Pharm will continue to pursue its strategy of increasing the proportion of sales of improved new drugs. It aims to increase the share of improved drugs to 70 percent by 2026 from about 60 percent in 2024.